###begin article-title 0
###xml 139 146 139 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Physiological studies in heterozygous calcium sensing receptor (CaSR) gene-ablated mice confirm that the CaSR regulates calcitonin release in vivo
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
The calcium sensing receptor (CaSR) regulates serum calcium by suppressing secretion of parathyroid hormone; it also regulates renal tubular calcium excretion. Inactivating mutations of CaSR raise serum calcium and reduce urine calcium excretion. Thyroid C-cells (which make calcitonin) express CaSR and may, therefore, be regulated by it. Since calcium stimulates release of calcitonin, the higher blood calcium caused by inactivation of CaSR should increase serum calcitonin, unless CaSR mutations alter the responsiveness of calcitonin to calcium.
###end p 2
###begin p 3
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 158 161 158 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 173 177 173 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 253 258 <span type="species:ncbi:10090">mouse</span>
To demonstrate regulatory effects of CaSR on calcitonin release, we studied calcitonin responsiveness to calcium in normal and CaSR heterozygous-ablated (Casr+/-) mice. Casr+/- mice have hypercalcemia and hypocalciuria, and live normal life spans. Each mouse received either 500 mul of normal saline or one of two doses of elemental calcium (500 mumol/kg or 5 mmol/kg) by intraperitoneal injection. Ionized calcium was measured at baseline and 10 minutes, and serum calcitonin was measured on the 10 minute sample.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 17 21 17 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 279 283 279 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 283 287 283 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 509 513 509 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
At baseline, Casr+/- mice had a higher blood calcium, and in response to the two doses of elemental calcium, had greater increments and peak levels of ionized calcium than their wild type littermates. Despite significantly higher ionized calcium levels, the calcitonin levels of Casr+/- mice were consistently lower than wild type at any ionized calcium level, indicating that the dose-response curve of calcitonin to increases in ionized calcium had been significantly blunted or shifted to the right in Casr+/- mice.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
These results confirm that the CaSR is a physiological regulator of calcitonin; therefore, in response to increases in ionized calcium, the CaSR inhibits parathyroid hormone secretion and stimulates calcitonin secretion.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Ionized calcium concentration of extracellular fluid is tightly regulated, subject to minute-to-minute control in order to maintain such diverse processes as cell membrane integrity, neuromuscular transmission and blood coagulation [1]. Small decreases in ionized calcium provoke excitability of the nervous system that can manifest as paresthesias and seizures; in contrast, increases in ionized calcium dampen nervous system responses and lead to such manifestations as constipation, obtundation, and coma. Parathyroid hormone (PTH) and calcitonin have long been recognized to respond quickly (but in opposite directions) to increases or decreases in ionized calcium [1-3].
###end p 9
###begin p 10
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
The "homeostat" that controls ionized calcium has been recognized to be the calcium sensing receptor (CaSR), a G protein-coupled, seven transmembrane-spanning receptor that binds calcium ions [4]. CaSR mRNA and protein are expressed by parathyroid chief cells that produce PTH. Binding of calcium activates the CaSR; consequently, an increase in ionized calcium leads to more activation of the receptor and, thereby, inhibition of PTH secretion. Conversely, a fall in ionized calcium leads to less activation of the receptor, and PTH escapes from inhibitory control. In the long-term, the CaSR also regulates the growth of parathyroid cells and the synthesis of PTH.
###end p 10
###begin p 11
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 647 648 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Since the original cloning of the CaSR by Dr. Edward Brown and colleagues at Harvard [5], it has been recognized that CaSR mRNA is also expressed by the C-cells of the thyroid, the source of calcitonin [6]. Furthermore, cells from a medullary thyroid carcinoma cell line express CaSR mRNA and release calcitonin in response to calcium [7]. The presence of the CaSR on C-cells raises the possibility that the CaSR might directly regulate calcitonin release; however, Dr. Brown has noted that the presence of the CaSR in a cell whose function is modulated by calcium is not sufficient proof that the CaSR mediates that particular action of calcium [4].
###end p 11
###begin p 12
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The regulation of calcitonin is opposite to that of PTH, in that increases in ionized calcium stimulate calcitonin, and decreases in ionized calcium lead to a fall in calcitonin. This observation led to the general assumption that the mechanisms mediating calcium sensing in parathyroid and C cells are distinctly different, with the latter likely involving some form of voltage-sensitive calcium channels [4,8]. It was, therefore, somewhat unexpected that the parathyroid CaSR would turn out to be expressed by C cells of the thyroid. Because calcium is the primary stimulus for changes in calcitonin, and the C cells express the CaSR, the CaSR is a logical and obvious candidate to fulfill the homeostatic regulatory function that it also does for PTH [4,8,9].
###end p 12
###begin p 13
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 155 158 155 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr </italic>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 425 430 <span type="species:ncbi:9606">human</span>
To address the issue of a role for the CaSR in regulating calcitonin in vivo, we utilized the calcium receptor gene ablation model [10]. Heterozygous (Casr+/-) mice have increased ionized calcium, modest hyperparathyroidism, and reduced renal calcium excretion. Homozygous (Casr null) mice have severe hypercalcemia and hyperparathyroidism, and die within several weeks of birth. These two conditions mimic the corresponding human conditions in which CaSR function is impaired or absent, respectively familial hypocalciuric hypercalcemia and neonatal severe hypercalcemia [5].
###end p 13
###begin p 14
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 148 152 148 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
We addressed the hypothesis that the CaSR stimulates calcitonin release in response to an increase in the blood calcium concentration. Thus, in Casr+/- mice, we expected to see that the calcitonin response to an increase in blood calcium would be blunted compared to the normal response, or shifted to the right. This is in fact what was observed.
###end p 14
###begin title 15
Results
###end title 15
###begin p 16
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 467 471 467 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr </italic>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
It was anticipated that provoking a calcitonin response by calcium injection would demonstrate that ablation of the CaSR had altered the normal relationship between ionized calcium and calcitonin levels. Such an experiment was not practical in fetuses because 3-4 fetal samples would have to be pooled for each calcitonin measurement. Instead, adults were used so that larger blood samples suitable for assay would be obtained. This meant that only wild type and Casr+/- mice could be studied, because Casr null mice are visibly ill within days of birth and die by two to three weeks of age.
###end p 16
###begin p 17
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 4 8 4 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 342 346 342 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 403 407 403 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 419 420 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 519 520 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 599 603 599 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 883 887 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 887 891 887 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 980 984 980 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 984 988 984 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
###xml 891 895 <span type="species:ncbi:10090">mice</span>
Casr+/- mice had higher ionized calcium levels at baseline compared to wild type, consistent with the known phenotype of these mice in both the original C57BL/6 background [10] and in the Black Swiss background [11]. The saline injection did not significantly alter ionized calcium, although the mean value dropped for both wild type and Casr+/- mice, and appeared to be proportionately greater for Casr+/- mice (Table 1). The two different doses of calcium resulted in significant elevations in ionized calcium (Table 1) compared to baseline and compared to the effect of the saline injection. Casr+/- mice had proportionately greater increments in ionized calcium and reached higher peak ionized calcium levels as compared to wild type. Thus, the higher baseline ionized calcium, the greater increments in ionized calcium, and the higher peak values in ionized calcium achieved by Casr+/- mice biased the experiment in favour of obtaining a higher peak calcitonin response from Casr+/- as compared to wild type.
###end p 17
###begin p 18
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 83 87 83 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 263 267 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 267 271 263 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 296 297 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 348 350 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 369 373 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 373 377 369 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 570 574 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 574 578 570 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 629 631 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 683 687 677 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 687 691 681 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
The mean baseline (post-saline) serum calcitonin levels were slightly lower in Casr+/- mice as compared to wild type, at 12.1 +/- 8.0 versus 20.4 +/- 8.9 pg/ml, respectively (p = 0.49). In response to calcium injection, the calcitonin level rose in wild type and Casr+/- mice as expected (Figure 1). A logarithmic scatterplot of the data in Figure 1A demonstrates that Casr+/- mice achieved lower calcitonin levels for each level of ionized calcium, and regression analysis confirmed that the dose-response curve for calcitonin was shifted significantly to the right in Casr+/- mice. The mean (+/- SE) data are plotted in Figure 1B, and confirm shift of calcitonin responsiveness in Casr+/- mice.
###end p 18
###begin title 19
Discussion
###end title 19
###begin p 20
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 46 50 46 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 238 242 238 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 242 245 242 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 426 430 426 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1054 1058 1054 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1058 1062 1058 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10116">rats</span>
###xml 1062 1066 <span type="species:ncbi:10090">mice</span>
These observations in adult wild type and Casr+/- mice demonstrate a definite shift in the physiological response of calcitonin to acute increments in ionized calcium. Since this response was dependent upon the genotype (wild type versus Casr+/-), it is clear that ablation of the CaSR was the determinant that shifted calcitonin responsiveness. The "shift to the right" in calcitonin responsiveness between wild type and Casr+/- mice confirms that the CaSR is a physiological regulator of calcitonin release. These observations complement and confirm the earlier observations of Lavigne et al, who demonstrated that the calcimimetic compound NPS R-467 stimulates calcitonin release in rats [12]. NPS R-467 activates the CaSR and suppresses PTH release; it was reasonably inferred from those experiments that NPS R-467 was stimulating the release of calcitonin through direct actions on the CaSR. The possibility that calcitonin was not stimulated directly by NPS R-467 could not be completely excluded in those experiments, and thus, our experiments in Casr+/- mice provide physiological evidence that the calcitonin response is dependent upon the CaSR.
###end p 20
###begin p 21
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1018 1022 1018 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1022 1026 1022 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1164 1168 1164 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1168 1172 1168 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1442 1446 1442 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1446 1450 1446 1450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1671 1673 1671 1673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 72 78 <span type="species:ncbi:9606">humans</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1108 1112 <span type="species:ncbi:10090">mice</span>
###xml 1172 1176 <span type="species:ncbi:10090">mice</span>
###xml 1184 1192 <span type="species:ncbi:9606">patients</span>
###xml 1450 1454 <span type="species:ncbi:10090">mice</span>
###xml 1554 1560 <span type="species:ncbi:9606">humans</span>
###xml 2293 2301 <span type="species:ncbi:9606">patients</span>
###xml 2398 2402 <span type="species:ncbi:10090">mice</span>
###xml 2539 2543 <span type="species:ncbi:10090">mice</span>
###xml 2555 2561 <span type="species:ncbi:9606">humans</span>
The effect of inactivating mutations of the CaSR on serum calcitonin in humans has not been extensively or rigorously examined, apart from noting that individuals with hypercalcemia due to familial hypocalciuric hypercalcemia (FHH) had apparently normal baseline calcitonin levels using older calcitonin radioimmunoassays [13-15]. In the first study [13], baseline calcitonin levels in 12 individuals with FHH were no different than in 9 unaffected individuals from the same kindred. In the second study [14], no calcitonin measurements were obtained from normal or unaffected individuals, but instead the results of FHH individuals were simply reported as being within the (at the time) wide normal range of < 69 pg/ml. In the third cited study, the baseline calcitonin levels in 26 individuals with FHH were compared to 20 unrelated healthy controls. The lack of a difference in baseline serum calcitonin levels in all three of these studies is similar to our observation that, at baseline, the calcitonin levels in Casr+/- mice are slightly lower but not significantly different than in related wild type mice. The presence of hypercalcemia at baseline in both Casr+/- mice and in patients with FHH should have caused a higher calcitonin level if the CaSR had normal sensitivity to calcium and normal function. It is only with the calcium challenge that the blunted calcitonin responsiveness became definitively apparent in our studies of Casr+/- mice. A 5 minute calcium challenge with calcitonin response was performed in only one of the studies in humans with FHH but was reported to show no difference in calcitonin response compared to unrelated normal controls [15]. Interestingly, in that study the mean results were actually lower in affected individuals, being 33.6 +/- 7.0 pg/ml in 7 normal males versus 18.6 +/- 5.4 pg/ml in 6 affected males with FHH, and 9.8 +/- 5.4 pg/ml in 7 normal females versus 7.9 +/- 2.7 pg/ml in 7 affected females with FHH. Thus, the low sample size number is likely a key reason why that study did not demonstrate these apparent differences to be statistically significant. That study, performed more than 13 years ago, may also have failed to demonstrate a difference due to the earlier-generation calcitonin assay used, and the heterogeneity of the patients under study (unrelated controls) as compared to the current study that used genetically related mice. The possibility of a species difference cannot be excluded; that is, that the CaSR is a significant regulator of calcitonin release in mice but not in humans.
###end p 21
###begin p 22
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 81 85 81 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 284 288 284 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
An alternative explanation for our findings is that chronic hypercalcemia in Casr+/- mice downregulated the responsiveness of calcitonin through indirect effects, such as by downregulation of another calcium sensor that in turn might regulate calcitonin. As shown in Table 1, the Casr+/- mice normally maintain a 0.1 mmol/l higher ionized calcium concentration than in wild-type, but acutely achieved a peak increment in ionized calcium that was approximately 0.4 mmol/l higher than the post-saline value. Therefore, because the acute stimulus (increase in ionized calcium) was much greater than the chronic stimulus (mild hypercalcemia), it is likely that the blunted calcitonin response is specific to heterozygous ablation of the CaSR, and not due to chronic hypercalcemia.
###end p 22
###begin p 23
Our current findings that ablation of the CaSR shifts the responsiveness of calcitonin to acute changes in the serum calcium predicts that the CaSR will be coupled to different signal transduction pathways depending upon the tissue in which it is expressed. In that way, the same receptor can have an inhibitory response to its activation in parathyroid cells, but a stimulatory response to its activation in parafollicular cells of the thyroid.
###end p 23
###begin p 24
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 4 8 4 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 235 239 235 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 366 370 366 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 490 494 490 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1000 1004 1000 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1004 1008 1004 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1014 1018 1014 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1018 1022 1018 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1267 1271 1267 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 1271 1275 1271 1275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:10116">rats</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
###xml 1022 1026 <span type="species:ncbi:10090">mice</span>
###xml 1275 1279 <span type="species:ncbi:10090">mice</span>
Casr+/- mice had greater increments in ionized calcium in response to the same dose of calcium given to wild type mice. The slightly greater (but statistically insignificant) drop in ionized calcium provoked by saline injection in Casr+/- mice may indicate a difference in intravascular volume that was not apparent by the normal hematocrit and body weight that Casr+/- mice have as compared to their siblings [10](and data not shown). Alternatively, the blunted calcitonin response of Casr+/- mice may in turn lead to loss of effect of calcitonin to promote calciuresis and minimize increases in the blood calcium. The role of calcitonin to minimize increases in the blood calcium in response to a calcium or PTH challenge has been demonstrated in mice lacking calcitonin through a genetic ablation [16]; and in rats rendered calcitonin deficient through surgical or immunological techniques [17,18]. The renal tubular action of the CaSR may also partly account for the greater calcemic response of Casr+/- mice. Casr+/- mice have reduced renal calcium excretion due to ablation of the CaSR [10,11], and thereby would be expected to have an impaired ability to excrete calcium in response to a calcium load. Furthermore, PTH-mediated bone resorption is increased in Casr+/- mice, which indicates that efflux of calcium from bone is increased, and bone matrix will be less able to take up calcium in response to a calcium load [10,11].
###end p 24
###begin p 25
###xml 521 523 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 591 593 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 715 717 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 931 933 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1868 1870 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1871 1873 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">Mice</span>
###xml 596 600 <span type="species:ncbi:10090">Mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
Although calcitonin has often been considered to be a vestigial hormone with no certain role in mammalian calcium and bone homeostasis, this study demonstrates that calcitonin is subject to physiological regulation by the CaSR. Recent studies in mice indicate that calcitonin has important roles in calcium and bone homeostasis that have not been previously recognized. Mice lacking the gene encoding calcitonin and calcitonin gene-related peptide-alpha (CGRP-alpha) develop a phenotype of increased bone mass as adults [16], a phenotype that is not present at the end of fetal development [19]. Mice that are heterozygous for loss of the calcitonin receptor also have a phenotype of increased bone mass as adults [20]. Preliminary studies have indicated that mice lacking the gene encoding calcitonin and CGRP-alpha lose more than twice as much skeletal calcium content as their wild-type sisters during three weeks of lactation [21], confirming a previously postulated role that calcitonin might protect the maternal skeleton from excessive resorption during lactation. Thus, calcitonin has new and emerging evidence of its importance in regulating calcium homeostasis and bone mass. It may be inferred that the CaSR regulates bone mass through its effect on the parathyroid glands to produce PTH, and through its effect on C-cells of the thyroid to produce calcitonin. In the short-term, the CaSR regulates ionized calcium concentration in blood by altering the release of PTH and calcitonin; in the long-term, it influences the maintenance of bone mass through these same hormones. In the future, pharmacological agents that can manipulate the CaSR to achieve an ideal balance of calcitonin and PTH in the circulation may provide a novel approach to treating disorders such as osteoporosis, secondary (uremic) hyperparathyroidism, hypercalcemia, and hypocalcemia [22,23].
###end p 25
###begin title 26
Conclusions
###end title 26
###begin p 27
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 53 57 53 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 193 197 193 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
In summary, we found that in adult wild type and Casr+/- mice an acute calcium injection stimulated the release of calcitonin, but the response curve was blunted or shifted to the right in Casr+/- mice. We have confirmed that the CaSR stimulates calcitonin release in response to an increase in the blood calcium concentration. Therefore, the CaSR has a dual physiological response to acute increases in ionized calcium, which includes inhibition of PTH release and stimulation of calcitonin release. In the long-term, the actions of the CaSR to regulate PTH and calcitonin will influence the maintenance of skeletal mineral content.
###end p 27
###begin title 28
Methods
###end title 28
###begin title 29
###xml 5 9 <span type="species:ncbi:10090">mice</span>
Casr mice
###end title 29
###begin p 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr </italic>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 296 300 296 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 105 111 <span type="species:ncbi:10090">murine</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
Casr-ablated mice were the gift of Jon Seidman (Harvard) and were obtained by targeted disruption of the murine Casr gene in stem cells, as previously described [10]. The mice were back-crossed into outbred Black Swiss strain (Taconic Labs) for at least five generations. Adult wild type and Casr+/- mice were used that were all first degree relatives of each other, and between 2 to 4 months of age. All mice were given a standard chow diet (1% calcium) and water. All studies were performed with the prior approval of the Animal Care Committee of Memorial University of Newfoundland.
###end p 30
###begin title 31
Calcium challenge experiments
###end title 31
###begin p 32
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 458 462 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 462 466 459 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
105 adult mice (37 wild type and 68 Casr+/-) were weighed and distributed into tertiles, to be given an intraperitoneal injection of either 500 mul of normal saline (0.9% sodium chloride), or one of two doses of elemental calcium (500 mumol/kg or 5 mmol/kg in 500 mul of normal saline). These doses of elemental calcium had been determined in preliminary experiments to result in significant increases in ionized calcium and calcitonin of both wild type and Casr+/- mice. Saline injection was used as the control group in order to control for alterations in ionized calcium that would occur due to the injection of fluid in the peritoneum and due to any stress on the animal caused by the experimental procedure. Tail blood was obtained at baseline and 10 minutes after the injection of elemental calcium to assay ionized calcium. Whole blood (near total blood volume) was obtained at 10 minutes by intracardiac needle for the calcitonin assay. The two separate blood collections (tail blood and intracardiac puncture) were performed at the 10 minute time point in order that the 10 minute ionized calcium measurements would be comparable to the baseline ionized calcium measurements. Tail blood and intracardiac blood do not provide comparable ionized calcium levels.
###end p 32
###begin title 33
Assays
###end title 33
###begin p 34
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 167 170 <span type="species:ncbi:10116">rat</span>
###xml 205 211 <span type="species:ncbi:10090">murine</span>
###xml 329 334 <span type="species:ncbi:10090">mouse</span>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
###xml 429 432 <span type="species:ncbi:10116">rat</span>
Ionized calcium was measured with a specific calcium ion electrode (Chiron 634 Ca++/pH Analyzer). Serum calcitonin was measured in duplicate using a specific IRMA for rat calcitonin that cross-reacts with murine calcitonin (Immutopics, San Clemente, CA) [12], and which has previously been validated in our laboratory for use on mouse serum [11,24]. In lieu of mouse calcitonin standards, values were expressed as pg-equivalents rat calcitonin/ml; the stated detection limit of the assay was 1.0 pg/ml.
###end p 34
###begin title 35
Statistical analysis
###end title 35
###begin p 36
Data was analyzed using SYSTAT 5.2.1 for Macintosh (SYSTAT Inc, Evanston, IL). Two-tailed probabilities are reported, and all data are presented as mean +/- SE.
###end p 36
###begin title 37
List of abbreviations
###end title 37
###begin p 38
CaSR Calcium sensing receptor
###end p 38
###begin p 39
PTH Parathyroid hormone
###end p 39
###begin p 40
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 4 8 4 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 8 12 <span type="species:ncbi:10090">Mice</span>
Casr+/- Mice that are heterozygous for deletion of CaSR gene
###end p 40
###begin p 41
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr </italic>
###xml 10 14 <span type="species:ncbi:10090">Mice</span>
Casr null Mice that are homozygous for deletion of CaSR gene
###end p 41
###begin p 42
CGRP-alpha calcitonin gene-related peptide-alpha
###end p 42
###begin p 43
FHH Familial hypocalciuric hypercalcemia
###end p 43
###begin p 44
SE standard error
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
NF carried out the physiological studies and participated in the writing of each draft of the manuscript. CK conceived of the study, directed it, and did the primary writing of the manuscript. Both authors approved the final draft of the manuscript.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
Supported by operating grants and a 5-year Scholarship (New Investigator Award) from the Canadian Institutes for Health Research (formerly Medical Research Council of Canada), and by funds from the Discipline of Medicine in the Faculty of Medicine at Memorial University of Newfoundland. The work described herein garnered the 2002 Antoni Nalecz Award from the Canadian Society of Endocrinology and Metabolism.
###end p 48
###begin article-title 49
Mineral balance and homeostasis
###end article-title 49
###begin article-title 50
Parathyroid hormone
###end article-title 50
###begin article-title 51
Calcitonin
###end article-title 51
###begin article-title 52
Extracellular Calcium Sensing and Extracellular Calcium Signaling
###end article-title 52
###begin article-title 53
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 76 82 <span type="species:ncbi:9913">bovine</span>
Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid
###end article-title 53
###begin article-title 54
Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene
###end article-title 54
###begin article-title 55
###xml 46 51 <span type="species:ncbi:9606">human</span>
Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion
###end article-title 55
###begin article-title 56
Is the calcium receptor a molecular target for the actions of strontium on bone?
###end article-title 56
###begin article-title 57
Calcium-sensing receptor
###end article-title 57
###begin article-title 58
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
###xml 17 22 <span type="species:ncbi:9606">human</span>
A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
###end article-title 58
###begin article-title 59
###xml 14 20 <span type="species:ncbi:10090">murine</span>
Regulation of murine fetal-placental calcium metabolism by the calcium-sensing receptor
###end article-title 59
###begin article-title 60
###xml 149 152 <span type="species:ncbi:10116">rat</span>
Stimulation of calcitonin secretion by calcium receptor activators: evaluation using a new, highly sensitive, homologous immunoradiometric assay for rat calcitonin
###end article-title 60
###begin article-title 61
Familial benign hypercalcaemia. Study of a large family
###end article-title 61
###begin article-title 62
Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families
###end article-title 62
###begin article-title 63
Calcium regulation of parathyroid and C cell function in familial benign hypercalcemia
###end article-title 63
###begin article-title 64
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene
###end article-title 64
###begin article-title 65
###xml 40 43 <span type="species:ncbi:10116">rat</span>
Calcium regulatory action of endogenous rat calcitonin demonstrated by passive immunization with calcitonin antibodies
###end article-title 65
###begin article-title 66
###xml 69 73 <span type="species:ncbi:10116">rats</span>
Ability of thyrocalcitonin to protect against hypercalcemia in adult rats
###end article-title 66
###begin article-title 67
Ablation of calcitonin/calcitonin gene related peptide-alpha impairs fetal magnesium but not calcium homeostasis
###end article-title 67
###begin article-title 68
Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo
###end article-title 68
###begin article-title 69
Calcitonin/calcitonin gene-related peptide protect the maternal skeleton from excessive resorption during lactation [abstract]
###end article-title 69
###begin article-title 70
The search for calcium receptor antagonists (calcilytics)
###end article-title 70
###begin article-title 71
The calcium receptor and calcimimetics
###end article-title 71
###begin article-title 72
Fetal parathyroids are not required to maintain placental calcium transport
###end article-title 72
###begin title 73
Figures and Tables
###end title 73
###begin p 74
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 41 45 41 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 165 169 165 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 516 520 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 520 524 516 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 694 698 690 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 698 702 694 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 874 878 870 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 878 882 874 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
Blunted calcitonin responsiveness in Casr+/- mice. On the left (1A), a logarithmic scatterplot of serum calcitonin versus ionized calcium level in wild type and Casr+/- mice. The straight lines indicate the respective best-fit regression lines; the respective 95% confidence intervals for the fitted lines are also shown, and have been demarcated by double-headed arrows for easier recognition. On the right (1B), a normal plot of mean serum calcitonin (+/- SE) versus mean ionized calcium (+/- SE) in wild type and Casr+/- mice. Vertical SE bars correspond to the calcitonin values, and horizontal error bars correspond to ionized calcium values. The peak calcitonin response of wild type and Casr+/- was significantly different for both ionized calcium and calcitonin (p < 0.02). In both graphs, the closed squares indicate wild type values, and the open squares indicate Casr+/- values.
###end p 74
###begin p 75
###xml 94 98 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Casr</italic>
###xml 98 102 96 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Mean (+/- SE) ionized calcium levels before (pre) and after (post) injection in wild type and Casr+/- mice. P values apply to the comparison of respective post versus pre values, and to the post values versus the corresponding post-saline value.
###end p 75

